A2A Pharmaceuticals names new president and chief executive officer
3 July 2019 -

A2A Pharmaceuticals Inc, a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents, announced yesterday that it has named Dr Sotirios G Stergiopoulos as its new president and chief executive officer.

Dr Stergiopoulos has held the position as founder and chairman of the board since 2016. He joins A2A from Ipsen where he served as the chief medical officer, SVP and head of Global Medical Affairs since January 2017. He has held numerous leadership positions in the pharmaceutical industry with companies including Novartis, Bayer, and Celgene.

Dr Stergiopoulos is a physician executive with a BS from Stony Brook University, an MD from Poznan University of Medical Sciences, and an MBEE from the Johns Hopkins University. He has trained at the National Institutes of Health, the Albert Einstein College of Medicine, and Harvard University.